Investors bought shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on weakness during trading on Friday. $93.31 million flowed into the stock on the tick-up and $55.86 million flowed out of the stock on the tick-down, for a money net flow of $37.45 million into the stock. Of all stocks tracked, Regeneron Pharmaceuticals had the 22nd highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($1.30) for the day and closed at $366.96
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Morgan Stanley restated an “equal weight” rating and set a $490.00 target price (up from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Jefferies Group restated a “hold” rating and set a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. SunTrust Banks restated a “hold” rating and set a $435.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 2nd. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $471.11.
The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The company has a market capitalization of $39,430.00, a PE ratio of 33.33, a PEG ratio of 1.45 and a beta of 1.52.
A number of hedge funds have recently added to or reduced their stakes in the business. DnB Asset Management AS purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $9,136,000. Atlantic Trust Group LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $3,560,000. Parametric Portfolio Associates LLC raised its holdings in shares of Regeneron Pharmaceuticals by 13.4% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 166,812 shares of the biopharmaceutical company’s stock valued at $74,585,000 after purchasing an additional 19,729 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 54,532 shares of the biopharmaceutical company’s stock valued at $24,382,000 after purchasing an additional 244 shares in the last quarter. Finally, Americafirst Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $700,000. Institutional investors own 66.63% of the company’s stock.
WARNING: This piece was originally reported by Week Herald and is owned by of Week Herald. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://weekherald.com/2018/01/12/investors-buy-shares-of-regeneron-pharmaceuticals-regn-on-weakness.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.